Co-creating Value with Stakeholders

To realize our Vision for Kyowa Kirin, we need to create both social and economic value. An essential part of this process is cooperating and collaborating with stakeholders in the value chain. We are committed to mutual understanding and deepening our relationship with stakeholders through various communication opportunities.

Our Key Stakeholders and Communication Opportunities

People facing illness: Patients, caregivers, patient communities、Healthcare professionals. Life-changing value, Patient-centric. Employees: Employees. Engagement, Skills development. Business partners: Partners (suppliers and distributor), Research, Development, and Sales Partners. Equitable business transactions, Co-creation of life-changing value. Capital providers: Shareholders / investors. Increase corporate value, Shareholder returns. Policymakers, industry associations: Central and local governments, Regulators / payers, Industry associations. Improving QOL of patients by providing appropriate medicines, Maintain and improve the public health care system. Community, Environment: Communities, Future generations / environment.Coexisting with local communities, Reducing environmental impact

You can see this table by scrolling horizontally.

Stakeholders Main communication opportunities and frequency
Patients, caregivers, patient communities
Disease and health information websites
 Ongoing
Medical information contact center
 Ongoing
Patient advocacy activities
 Ongoing
Healthcare professionals
Medical websites
 Ongoing
Medical information contact center
 Ongoing
Publication of medical findings in journals and at conferences
 Ongoing
Communication via MR/MSL
 Ongoing
Employees
Internal intranet
 Ongoing
Whistleblowing system*1
 Ongoing
Awards for employees
 1 time
Employee engagement survey
 1 time
Interviews with superiors and team members
 Ongoing
Labor-management talks
 Ongoing
Partners
(suppliers and distributor)
Supplier briefings
 1 time
Sustainable procurement questionnaire
 1 time
Collaboration on business transactions
 Ongoing
Research, development, and sales partners
Partnerships in pharmaceutical research and development
 Ongoing
Shareholders / investors
General meeting of shareholders
 1 time
Financial results briefings
 4 times
IR events for R＆D and sustainability topic
 4 times
IR interviews with the president
 20 times
IR interviews with management
 18 times
IR interviews by officer in charge of IR
 144 times
Central and local governments, regulators / payers, industry associations
Advocacy and collaboration through industry bodies
 Ongoing
Communities
Initiatives to support communities
 Ongoing
Dialogue with local residents
 Ongoing
Future generations / environment
Initiatives to support communities
 Ongoing
Climate change response and other environmental measures
 Ongoing
  • *1
    The Company has also established a whistleblower system for stakeholders as part of its grievance mechanism.

Links between stakeholders and the value chain

Creating value relies heavily on cooperation and collaboration with various stakeholders. Here we illustrate the connections between stakeholders who play a central role in value creation and the value chain as defined by our business model and value creation story.

In particular, we believe that in order to continue creating life-changing value that makes people facing illness smile, it is necessary to listen carefully to their voices at various stages of the value chain. This idea is illustrated in the figure below. Under the concept of Patient Centricity, we will create value together with our stakeholders.

Initiatives and Industry Associations

Through our involvement in initiatives and industry associations, we understand the demands of our stakeholders and apply them to our group's business activities. In addition, through collaboration with initiatives and industry associations, we will address social issues that are difficult for individual companies to resolve on their own.

Initiatives

Participation as Kyowa Kirin
  • Task Force on Climate-related Financial Disclosures (TCFD)
  • World Anti Doping Agency (WADA)
  • Pharmaceutical Supply Chain Initiative (PSCI)
Participation as the Kirin Group
  • The United Nations Global Compact*
  • RE100
  • Science Based Targets initiative (SBTi)
  • *
    The Kirin Group, to which our Group belongs, has announced participation in the United Nations Global Compact since September 2005. As a member of the Kirin Group, we observe the 10 principles of the United Nations Global Compact, which address human rights, labor, the environment, and anticorruption

Industry Associations

  • Japan Business Federation
  • FPMAJ (The Federation of Pharmaceutical Manufacturers' Associations of JAPAN)
  • JPMA (Japan Pharmaceutical Manufacturers Association)
  • PMAT (The Pharmaceutical Manufactureres' Association of Tokyo)